About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)

NYSE: PTN)" src="https://www.abnewswire.com/upload/2025/03/1743208015.jpg" alt="Palatin Technologies' UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data - Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)" width="225" height="225">
Palatin's oral PL8177 treatment just posted jaw-dropping results for ulcerative colitis with a 78% clinical response rate, 33% remission rate, and zero side effects. Multiple "big pharma" companies are already circling for licensing deals. A potential revolution for 1.25 million UC sufferers could be brewing, with obesity trial results due any moment.

Palatin Technologies (NYSE American: PTN)* just unveiled remarkable topline results from its Phase 2 study of PL8177 for ulcerative colitis (UC), demonstrating what could be a disruptive new treatment approach for this debilitating inflammatory bowel condition.

The data seems impressive - an extraordinary 78% of patients treated with PL8177 achieved clinical response compared to just 33% for placebo, with statistical significance (p<0.005). Even more encouraging, 33% of treated patients reached full clinical remission while none of the placebo patients did. The treatment also demonstrated a perfect safety record with zero adverse events reported, a crucial advantage in a therapeutic area plagued by treatments with serious side effects.

"We are thrilled with the positive results in this study, especially the meaningful and high rates of achievement for clinical remission and clinical response," stated Carl Spana, Ph.D., President and CEO of Palatin, in the company's announcement. "Most patients showed significant symptom and endoscopic score improvements after just eight weeks of treatment."

Palatin's approach with PL8177, which targets the melanocortin-1 receptor (MC1R), represents a completely novel mechanism in the UC treatment landscape. This once-daily oral medication could revolutionize care for the approximately 1.25 million Americans suffering from UC, particularly the 350,000+ diagnosed with moderate-to-severe disease who currently face limited and often problematic treatment options.

The results were especially striking in patients with more extensive disease. Among those with inflammation in all three colon segments, 60% of PL8177-treated patients showed improvement across all segments, and a remarkable 80% improved in at least two segments. Not a single placebo patient showed comparable improvement.

"Seeing a good percentage of patients treated with PL8177 achieve strong results for clinical remission and clinical response in this short study on UC patients is a compelling indicator that melanocortin-1 receptor agonists could be a promising treatment option for UC," noted Dr. Dana J. Lukin, Clinical Director of the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine-New York Presbyterian Hospital, in Palatin's release.

This breakthrough comes just days after Palatin received FDA orphan drug designation for another compound, PL7737, targeting obesity caused by leptin receptor deficiency. The company appears to be hitting its stride with its melanocortin receptor technology platform, which also shows promise in dry eye disease and diabetic nephropathy.

Perhaps most exciting for those following the company, Dr. Spana revealed that "several major pharmaceutical companies have shown strong interest in our UC program," suggesting that partnership or licensing deals might be imminent. For a small biotech with multiple promising programs, such deals could be transformative.

With Palatin also set to release results from its eagerly anticipated Phase 2 BMT-801 obesity study combining bremelanotide with tirzepatide any day now, the company is quickly emerging as one of biotech's most compelling stories of 2025.

 

 

Recent Palatin Technologies News Highlights:

 

*DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms

 

Media Contact
Company Name: Wall Street Wire
Contact Person: Editorial Staff
Email: Send Email
Country: United States
Website: https://newsletter.page/wallstreetalerts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.95
-4.08 (-1.84%)
AAPL  258.45
-4.32 (-1.64%)
AMD  230.23
-7.80 (-3.28%)
BAC  51.10
-0.42 (-0.82%)
GOOG  252.53
+1.19 (0.47%)
META  733.41
+0.14 (0.02%)
MSFT  520.54
+2.88 (0.56%)
NVDA  180.28
-0.88 (-0.49%)
ORCL  272.66
-2.49 (-0.90%)
TSLA  438.97
-3.63 (-0.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.